163554-55-0

Usage

Uses

Used in Organic Chemistry:
Carbamic acid, (1-formylcyclobutyl)-, 1,1-dimethylethyl ester (9CI) is used as a reagent in chemical reactions for its ability to react with a wide range of other chemicals, making it useful in the synthesis of various organic compounds.
Used in Pharmaceutical Industry:
Carbamic acid, (1-formylcyclobutyl)-, 1,1-dimethylethyl ester (9CI) is used as an intermediate in the synthesis of pharmaceutical compounds due to its versatile reactivity with other chemicals.
Used in Chemical Research:
Carbamic acid, (1-formylcyclobutyl)-, 1,1-dimethylethyl ester (9CI) is used as a research tool in chemical research to explore its reactivity and potential applications in the development of new organic compounds and materials.

Upstream product

• 1142211-17-3 tert-butyl (1-(hydroxymethyl)cyclobutyl)carbamate 
• 120728-10-1 1-[(tert-butoxycarbonyl)amino]cyclobutanecarboxylic acid 
• 1232365-37-5 tert-butyl N-[1-[methoxy(methyl)carbamoyl]cyclobutyl]carbamate 
• 54450-84-9 ethyl hydrogen cyclobutane-1,1-dicarboxylate 
• 163554-54-9 ethyl 1-[(tert-butoxycarbonyl)amino]cyclobutanecarboxylate 

Relevant academic research and scientific papers

Selective cathepsin s inhibition with MIV-247 attenuates mechanical allodynia and enhances the antiallodynic effects of gabapentin and pregabalin in a mouse model of neuropathic pain

Cathepsin S inhibitors attenuate mechanical allodynia in preclinical neuropathic pain models. The current study evaluated the effects when combining the selective cathepsin S inhibitor MIV-247 with gabapentin or pregabalin in a mouse model of neuropathic pain. Mice were rendered neuropathic by partial sciatic nerve ligation. MIV-247, gabapentin, or pregabalin were administered alone or in combination via oral gavage. Mechanical allodynia was assessed using von Frey hairs. Neurobehavioral side effects were evaluated by assessing beamwalking. MIV-247, gabapentin, and pregabalin concentrations in various tissueswere measured. Oral administration of MIV-247 (100-200 μmol/kg) dose-dependently attenuated mechanical allodynia by up to approximately 50%reversal when given as a single dose or when given twice daily for 5 days. No behavioral deficits were observed at any dose of MIV-247 tested. Gabapentin (58-350 μmol/kg) and pregabalin (63-377 μmol/kg) also inhibited mechanical allodynia with virtually complete reversal at the highest doses tested. The minimum effective dose of MIV-247 (100 μmol/kg) in combination with the minimum effective dose of pregabalin (75 μmol/kg) or gabapentin (146 μmol/kg) resulted in enhanced antiallodynic efficacy without augmenting side effects. A subeffective dose of MIV-247 (50 μmol/kg) in combination with a subeffective dose of pregabalin (38 μmol/kg) or gabapentin (73 μmol/kg) also resulted in substantial efficacy. Plasma levels of MIV-247, gabapentin, and pregabalin were similar when given in combination as to when given alone. Cathepsin S inhibition with MIV-247 exerts significant antiallodynic efficacy alone, and also enhances the effect of gabapentin and pregabalin without increasing side effects or inducing pharmacokinetic interactions.

CYSTEINE PROTEASE INHIBITORS

Compounds of the formula (I) wherein One of A1 and A2 is N-CH3 and the other is CH; R1 is C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl or oxetan-3-yl, wherein C3-C6cycloalkyl is optionally substituted with one, two or three fluoro or with CF3; R2a and R2b are independently selected from H, halo, C1-C4alkyl, C1-C4haloalkyl and C1- C4alkoxy; R3 is CH3 or F; n is 1, 2, 3 or 4; or a pharmaceutically acceptable salt, hydrate or N-oxide thereof for the use in the prophylaxis and/or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.

CYSTEINE PROTEASE INHIBITORS

Compounds of the formula (I) wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and Rs

CYSTEINE PROTEASE INHIBITORS

Compounds of Formula (II) wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R

NEW CATHEPSIN S PROTEASE INHIBITORS, USEFUL IN THE TREATMENT OF E.G. AUTOIMMUNE DISORDERS, ALLERGY AND CHRONIC PAIN CONDITIONS

Compounds of the formula (I) wherein R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together wi

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds having antibacterial activity are disclosed. The compounds have the following structure (I) including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, Q5, R1, R2, R3, Z1 and Z2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (Formula (I)), including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3, Z1 and Z2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS

Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): (Formula (I)), including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q1, Q2, R1, R2, R3, Z1 and Z2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

TREATMENT OF URINARY TRACT INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS

A method for treating a urinary tract infection in a mammal in need thereof is disclosed, the method comprising administering to the mammal an effective amount of an antibacterial aminoglycoside compound.

CYSTEINE PROTEASE INHIBITORS

Compounds of the formula I wherein R1a is H; and R1b is C1-C6 alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and Rsu